Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Insider Sells 2,000 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 2,000 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $61.61, for a total transaction of $123,220.00. Following the sale, the insider now owns 83,277 shares in the company, valued at $5,130,695.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded down $0.05 during midday trading on Wednesday, reaching $61.66. The stock had a trading volume of 98,614 shares, compared to its average volume of 136,964. The firm has a 50 day simple moving average of $66.50 and a 200-day simple moving average of $59.62. ANI Pharmaceuticals, Inc. has a one year low of $44.27 and a one year high of $70.81. The firm has a market cap of $1.29 billion, a PE ratio of 38.54 and a beta of 0.80. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The company had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. HC Wainwright raised their target price on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $81.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Pacer Advisors Inc. bought a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $41,000. AJOVista LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth about $58,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $106,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 361.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 1,854 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter worth about $132,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.